期刊名称：AUTOIMMUNITY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Current understanding of autoimmune disease is being increasingly underpinned by the new molecular sciences. Progress in this area has been little short of spectacular, and all clinical specialities now recognise autoimmunity as a major component of the diseases with which they are involved.
Autoimmunity is an international, peer reviewed journal that publishes articles of clinical and basic science on the pathogenesis, immunology, genetics, molecular biology, and treatment of autoimmune diseases. In addition to the basic mechanisms and elements of the immune system, the journal focuses on the autoimmune processes associated with systemic lupus erythematosus, rheumatoid arthritis, Sjogren syndrome, diabetes, multiple sclerosis, and other systemic and organ-specific autoimmune diseases. The journal is not restricted to any disease type or clinical speciality, but reflects the areas where scientific progress is most rapid and clinical applications significant and widespread.
The journal is valuable to clinicians and researchers in immunology and molecular biology.
Abstracting & Indexing
Autoimmunity is abstracted in: Cambridge Scientific Abstracts; Current Awareness in Biological Sciences (CABS); Current Contents; Excerpta Medica; Index Medicus/MEDLINE; PubMed; PASCAL; Reference Update, Scopus, Science Citation Index and SIIC.
Instructions to Authors
Types of Contributions
Full length research papers will be published, describing in detail original research work and usually not more than 30 double spaced pages in length. Short communications may be published at the discretion of the Editorial Board if these describe complete and original work whose length does not justify a full length paper. Each issue of Autoimmunity will usually contain a short, concise review article, written at the invitation of the Editor. Hypotheses of up to 3000 words, provided they are well founded, will be published from time to time with the aim of stimulating new thought-provoking correspondence. Authors wishing to submit either a review article or a hypothesis should forward a summary to the Editor before starting detailed work on the manuscript. Correspondence will be encouraged as "Letters to the Editor". Papers are accepted only in English.
Submission of Manuscripts
All submissions should be made online at Autoimmunity’s Manuscript Central site. New users should first create an account. Once a user is logged onto the site submissions should be made via the Author Centre.
Preparation of Manuscripts
Contributors are strongly encouraged to read these instructions carefully before preparing a manuscript for submission, and to check the manuscript for compliance with these notes before submitting it for publication.
Autoimmunity considers all manuscripts on the strict condition that they have been submitted only to Autoimmunity, that they have not been published already, nor are they under consideration for publication or in press elsewhere. Authors who fail to adhere to this condition will be charged with all costs that Autoimmunity incurs and their papers will not be published.
Research article contributions to Autoimmunity must report original research. Research papers and review papers will be subjected to review by referees. The following guidelines apply:
i. Manuscripts should be double-spaced, with wide (3cm) margins. Submit with all files relating to the manuscript. The first page should be a Title Page with the title of the paper, the name, affiliation and address of each author, indicating with an asterisk and a footnote the full postal address of the author to whom proofs, correspondence and requests for reprints, etc., should be sent, and an additional shortened running title (usually not more than 35 characters including spaces). Also include 5 keywords or phrases, references and figures suitable for direct reproduction.
ii. All headings in the text should be set over to the left hand margin, and text should begin on the next line. Type first level (sectional) headings all in capitals. Second level headings should be typed in small (lower case) letters but with the first letter of each main word a capital. For third level headings, only the first letter of the first word should be a capital. Underline first and second level headings. Abstract is a required element for all papers.
FIRST LEVEL TEXT HEADING
Second Level Text Heading
Third level text heading
iii. All figures should be numbered with consecutive Arabic numbers, have descriptive captions, and be mentioned in the text. Keep figures separate from the text, but indicate an approximate position for each.
Preparation: Figures submitted must be of a high enough standard for direct reproduction. Digital images of high resolution should be used. Files should be saved as one of the following formats: TIFF (tagged image file format), PostScript or EPS (encapsulated PostScript), and should contain all the necessary font information and the source file of the application (e.g. CorelDraw/Mac, CorelDraw/PC). Redrawing or retouching of unusable figures will be charged to authors.
Size: Illustrations should be prepared to fit either into a single column width (75mm) or a double column width (160mm) with capital lettering 4mm high, to accommodate reduction. Photographs for halftone reproduction should be about twice the desired size.
Captions: A list of figure captions should be typed on a separate sheet and included in the typescript.
iv. Tables should be clearly typed with double spacing. Number tables consecutively with Arabic numerals, and give each a clear descriptive caption at the top. Avoid the use of vertical rules in tables.
v. For all manuscripts non-discriminatory language is mandatory. Sexist or racist terms should not be used.
vi. Papers are accepted only in English.
vii. Authors must adhere to SI units.
viii. For information on submitting animations, movie files and sound files or any additional information including indexes and calendars please click here.
ix. Drugs should be referred to by generic names; trade names of substances, their sources, and details of manufacturers of scientific instruments should be given if the information is important to the evaluation of the experimental data. When using a word which is or is asserted to be a proprietary term or trade mark authors must use the symbol ® or TM or alternatively a footnote can be inserted using the wording below:
This article includes a word that is or is asserted to be a proprietary term or trade mark. Its inclusion does not imply it has acquired for legal purposes a non-proprietary or general significance, nor is any other judgement implied concerning its legal status.
x. References should follow the CBE Citation & Sequence format. Only works actually cited in the text should be included in the references. Indicate in the text with Arabic numbers inside square brackets. Spelling in the reference list should follow the original. References should then be listed in numerical order at the end of the article. Examples are provided as follows:
Journal article:
[1] Steiner U, Klein J, Eiser E, Budkowski A, Fetters LJ. Complete wetting from polymer mixtures. Science 1992;258:1122-9.
Book chapter:
[2] Kuret JA, Murad F. Adenohypophyseal hormones and related substances. In: Gilman AG, Rall TW, Nies AS, Taylor P, editors. The pharmacological basis of therapeutics. 8th ed. New York: Pergamon; 1990. p 1334-60.
Conference proceedings:
[3] Irvin AD, Cunningham MP, Young AS, editors. Advances in the control of Theileriosis. International Conference held at the International Laboratory for Research on Animal Diseases; 1981 Feb 9-13; Nairobi. Boston: Martinus Nijhoff Publishers; 1981. 427 p.
Dissertations or Thesis:
[4] Mangie ED. A comparative study of the perceptions of illness in New Kingdom Egypt and Mesopotamia of the early first millennium [dissertation]. Akron (OH): University of Akron; 1991. 160 p. Available from: University Microfilms, Ann Arbor MI; AAG9203425.
Journal article on internet:
[5] Loker WM. "Campesinos" and the crisis of modernization in Latin America. Jour of Pol Ecol [serial online] 1996; 3(1). Available: http://www.library.arizona.edu/ej/jpe/volume_3/ascii-lokeriso.txt via the INTERNET. Accessed 1996 Aug 11.
Webpage:
[6] British Medical Journal [Internet]. Stanford, CA: Stanford Univ; 2004 July 10 - [cited 2004 Aug 12]; Available from: http://bmj.bmjjournals.com/
Internet databases:
[7] Prevention News Update Database [Internet]. Rockville (MD): Centers for Disease Control and Prevention (US), National Prevention Information Network. 1988 Jun - [cited 2001 Apr 12]. Available from: http://www.cdcnpin.org/db/public/dnmain.htm
Further examples and information can be found in the CBE style manual Scientific Style and Format, sixth edition.
xi. Authors are encouraged to minimise the use of footnotes. A footnote may include the designation of a corresponding author of a paper, current address information for an author (if different from that shown in the affiliation), and traditional footnote content. Information concerning grant support of research should appear in a separate Acknowledgements section at the end of the paper, not in a footnote. Acknowledgements of the assistance of colleagues or similar notes of appreciation also properly belong in an Acknowledgements section, not in the footnotes. They should be indicated in the text by the following symbols: * (asterisk or star), (dagger), (double dagger), ¶ (paragraph mark), § (section mark), || (parallels) # (number sign), for bibliographical reference call outs or exponents. Do not use numerals for footnote call outs as they may be mistaken. Type each footnote at the bottom of the typescript page on which its text call-out appears. Footnotes within a table should be indicated by the same symbols listed above. Reinitialise symbol sequence within tables. Type footnotes to a table directly beneath the table.
xii. Text call-outs to figures, tables and other elements are the basis for searching articles on electronic delivery. Therefore, proper designation of text call-outs to figures and other elements is essential to the success of electronic delivery. When referring to a figure, table or any other element within an article, always call the element by its full name: "See Table 1", "Figure 1 illustrates...", "Refer to Scheme 1". Do not use ambiguous call-outs (for example, "1 illustrates...") that do not clearly denote the element being referred to.
Ethics and Consent
When reporting experiments on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 1983. Do not use patients' names, initials, or hospital numbers, especially in illustrative material. Papers including animal experiments or clinical trials must be conducted with approval by the local animal care or human subject committees, respectively.
Identifying information should not be published in written descriptions, photographs, and pedigrees, unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Informed consent for this purpose requires that the patient be shown the manuscript to be published.
Disclosure of Potential Conflicts of Interest
It is the sole responsibility of authors to disclose any affiliation with any organisation with a financial interest, direct or indirect, in the subject matter or materials discussed in the manuscript (such as consultancies, employment, expert testimony, honoraria, speakers' bureaus, retainers, stock options or ownership) that may affect the conduct or reporting of the work submitted. If uncertain as to what might be considered a potential conflict of interest, authors should err on the side of full disclosure. Information about potential conflict of interest should be clearly stated at the point of submission (for example in a cover letter, or within the appropriate field on the journal's Manuscript Central site). This may be made available to reviewers and may be published with the manuscript at the discretion of the Editors.
Disclosure of Sources of funding
All sources of funding for research are to be explicitly stated, at the point of submission. This may be published with the manuscript at the discretion of the Editors.
Authorship Contributions
Contributions must be substantial in order to warrant authorship. Each author should have participated sufficiently in the work to take public responsibility for the content. All other contributors should be listed as acknowledgements.
Colour and Page Charges
Any figure submitted as a colour original will appear in colour in the Journals' online edition free of charge and can be downloaded. Paper copy colour reproduction will only be considered on condition that authors contribute to the associated costs. The charges are £500/US$1030 for the first colour page and £250/US$515 for each colour page after per article.
There are no charges for non-colour pages.
Proofs
The Editor reserves the right to proceed to press without submitting page proofs to the author. However, usual practice will involve corresponding authors receiving email notification with a password and Web address from which to download a PDF. Hard copies of proofs will not be mailed. To avoid delays in publication, corrections to proofs must be returned within 48 hours, by electronic transmittal, fax or mail. Authors will be charged for excessive correction at this stage of production.
If authors do not return page proofs promptly, the Editor reserves the choice to either delay publication to a subsequent issue or to proceed to press without author corrections.
Offprints and Reprints
Corresponding authors will receive free online access to their article through our website (www.informaworld.com). Reprints of articles published in this journal can be purchased through Rightslink® when proofs are received. If you have any queries, please contact our reprints department at Zoe.tzanev@informausa.com.
Copyright
It is a condition of publication that authors assign copyright or license the publication rights in their articles, including abstracts, to Informa Healthcare USA, Inc. This enables us to ensure full copyright protection and to disseminate the article, and the Journal, to the widest possible readership in print and electronic formats as appropriate. Authors may, of course, use the article elsewhere after publication without prior permission from Informa Healthcare USA, Inc., provided that acknowledgement is given to the Journal as the original source of publication, and that Informa Healthcare is notified so that our records show that its use is properly authorised. Authors retain a number of other rights under the Informa Healthcare USA, Inc. rights policies documents. These policies are referred to at the Copyright FAQs page.
Authors are themselves responsible for obtaining permission to reproduce copyright material from other sources. See Copyright Permission for full details.
A copyright agreement form can be downloaded by corresponding authors of accepted manuscripts with proofs. This should be signed and returned to Informa Healthcare.
Contacting the Publisher
Autoimmunity
Informa Healthcare
c/o Sharon Davis 16th Floor 52 Vanderbilt Ave. New York, NY 10017 Tel: (646) 957-8890 Email (Please include the Journal name in all correspondence.)
Editorial Board
Editor-in-Chief:
Paolo Casali, M.D. - Cornell University, Weill Medical College, 1300 York Avenue, Room C-302, New York NY 10021, USA
Regional Editors:
USA and Canada
Mary K. Crow, M.D. - Hospital for Special Surgery, 535 East 70th Street, Room 200 New York, NY 10021, USA
Europe
Angela Tincani, M.D - Division of Clinical Immunology, University Hospital, Piazza Spedali Civili 1, Brescia, Italy 25125
Asia
Takao Koike, M.D. - Department of Medicine, Hokkaido University, School of Medicine, N-15 W-7, Kita-ku, Sapporo, Japan 060-8638
Australia
Thomas W. Kay, Ph.D. - Department of Autoimmunity and Transplantation, The Walter and Eliza Hall Institute of Medicine, PO The Royal Melbourne Hospital, Parkville, Australia 3050
Latin America
Donato Alarcon-Segovia - Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran Vasco de Quiroga 15, Tlalpan, Mexico D.F, Mexico
Associate Editors:
G. Balestrieri - University Hospital, Brescia, Italy
J. A. Bluestone - University of California, San Francisco, CA, USA
C. A. Bona - Mt. Sinai School of Medicine, New York, NY, USA
M.B. Brenner - Harvard Medical School, Boston, MA, USA
P. D. Burrows - University of Alabama, Birmingham, AL, USA
J. D. Capra - Medical Research Foundation - Oklahoma City, OK, USA
A. Cerutti - Cornell University Weill Medical College, New York, NY, USA
N. Chiorazzi - North Shore-LIJ Research Institute, Manhasset, NY, USA
J. E. Craft - Yale University, New Haven, CT, USA
P. L. Cohen - University of Pennsylvania, Philadelphia, PA, USA
A. Cooke - University of Cambridge, UK
C. David - Mayo Clinic and Foundation, Rochester, MN, USA
A. Davidson - Albert Einstein College of Medicine, New York, NY, USA
S. K. Datta - Northwestern University Medical School, Chicago, IL, USA
R. Derksen - University Hospital, Utrecht, The Netherlands
B. Diamond - Albert Einstein College of Medicine, New York, NY, USA
A. Durandy - Hôspital Necker-Enfants Malades, Paris, France
K. Elkon - University of Washington, Seattle, WA, USA
R. S. Fujinami - University of Utah, Salt Lake City, UT, USA
C. G. Fathman - Stanford University, CA, USA
J. Gordon - University of Birmingham, UK
G. S. Gilkeson - Medical University South Carolina, Charleston, SC, USA
J. J. Goronzy - Mayo Clinic and Foundation, Rochester, MN, USA
D. Hafler - Harvard Medical School, Boston, MA, USA
J. Harley - Medical Research Foundation, Oklahoma City, OK, USA
W. K. Holloman - Cornell University Weill Medical College, New York, NY, USA
T. Honjo - Kyoto University, Japan
S. Izui - University of Geneva, Switzerland
A. E. Koch - Northwestern University Medical School, Chicago, IL, USA
B. L. Kotzin - University of Colarado, Denver, CO, USA
A. Lernmark - University of Washington, Seattle, WA, USA
M. Lockshin - The Barbara Volcker Center for Women and Rheumatic Disease, New York, NY, USA
P. Meroni - Universita degli Studi di Milano, Milan, Italy
D. Nemazee - Scripps Research Institute, La Jolla, CA, USA
J. M. Phillips-Quagliata - New York University, NY, USA
J-C. Piette - Hopital Pitie-Salpetriere, Paris, France
B. Prabhakar - University of Illinois, Chicago, IL, USA
W. H. Reeves - University of Florida, Gainsville, FL, USA
P. Riboldi - Universita degli Studi di Milano, Milan, Italy
N. R. Rose - School of Public Health, Baltimore, MD, USA
S. Sakaguchi - Kyoto University, Japan
J. E. Salmon - Hospital for Special Surgery, New York, NY, USA
M. J. Shlomchik - Yale University, New Haven, CT, USA
Y. Shoenfeld - Sheba Medical Center, Tel Hashomer, Israel
L. E. Silberstein - Harvard Medical School, Boston, MA, USA
F. Stevenson - University of Southampton, UK
A. Tarakhovsky - The Rockerfeller University, New York, NY, USA
M. Taussig - The Babraham Institute, Cambridge, UK
A. Tenner - University of California, Irvine, CA, USA
J. W. Thomas - Vanderbilt University, Nashville, NJ, USA
G. Valesini - Universita di Roma La Sapienza, Rome, Italy
D. Vergani - University College London, UK
E. K. Wakeland - University of Texas, Dallas, TX, USA
M. Weigert - Princeton University, NJ, USA
J. -W. Yoon - University of Calgary, Alberta, Canada
H. Zan - Cornell University Weill Medical College, New York, NY, USA
R. Zinkernagel - University Hospital, Zurich, Switzerland
Founding Editor:
Terence J. Wilkin - Derriford Hospital, Plymouth, UK
|
